COG AALL1521/INCB 18424-269: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

  • Hijiya, Nobuko (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date12/1/16 → 12/4/19

Funding

  • Children’s Hospital of Philadelphia
  • Incyte Corporation